DRD2 and Parkinson disease: Moreover, the ligand-directed labelling approach may provide opportunities to visualise localisation and trafficking of adenosine heteroreceptor complexes, for instance A2AR and dopamine D2 receptors heteromers, to support novel drug discovery for Parkinson’s disease and schizophrenia [17–19].